Study of GH55 for cancers with MAPK mutations
Part of Cancer clinical trials.
This trial tests a new drug, GH55, for people with advanced solid tumors that have a specific change in a group of genes called MAPK. It is for those who have tried other treatments or cannot have standard therapy. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have a solid tumor (like in the breast, lung, or colon) that has spread or cannot be removed, and it has a change in MAPK-related genes (RAS, RAF, MEK, or ERK).
- You have tried standard treatment and it stopped working, or there is no standard treatment, or you cannot take standard treatment.
- You are in fairly good health, able to take care of yourself (performance status 0-2 depending on the study phase).
- Your major organs (like bone marrow, liver, kidneys) are working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, GH55 and GH21, for people with advanced solid tumors that have changes in the MAPK signaling pathway (a cellular growth pathway). The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two targeted pills (GH21 and D-1553) for people with advanced solid tumors that have a specific KRAS G12C mutation, especially those who have already tried another KRAS G12C inhibitor. The goal is to see if the combo can shrink tumors more effectively.
This early-phase trial tests a new investigational drug (HMPL-415S1) in people with advanced solid tumors that have limited treatment options. It aims to see how the drug is tolerated and whether it can shrink tumors, especially in cases with KRAS-pathway changes.
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
This trial tests a combination of two drugs, GH21 and D-1553, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination works better than each drug alone.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors With MAPK Signal Pathway Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.